# Latest Online Documents — Articles and Official Sources

**Purpose:** Present recently found articles and official documents with titles, short summaries, and clickable links.  
**Focus:** HK–Mainland cooperation for rare disease drug access; policy and subsidy updates 2024–2025.  
**Note:** Sources already fully summarised in the Google Doc (summary2Feb.md) or moreDocs.md are not duplicated here; this list emphasises **new or recent** finds.

---

## Government / LegCo (info.gov.hk, legco.gov.hk)

### 1. LCQ22: Provision of drugs to patients (Oct 2025)
**Link:** [LCQ22: Provision of drugs to patients](https://www.info.gov.hk/gia/general/202510/22/P2025102200507.htm)  
**Summary:** LegCo Q&A on drug provision. Covers accelerating regulatory reform for drugs and medical devices, flexible approval for multi-indication drugs, cross-boundary medication services, and **drug price transparency**—including whether the Government will reference the Mainland’s practice of publishing official anti-cancer and rare disease drug price lists online. Relevant to the hypothesis on transparency and Mainland reference.

### 2. LCQ5: Providing treatment for patients experiencing relapses or deterioration of rare diseases (Sep 2025)
**Link:** [LCQ5: Rare disease relapses](https://www.info.gov.hk/gia/general/202509/10/P2025091000562.htm)  
**Summary:** Government reply on A&E and treatment for rare disease patients in relapse (e.g. neuromyelitis optica). HA Rare Diseases Database references Mainland’s National Lists (207 entities); CMS recorded ~63,600 cases (as at 30 Jun 2025). Multi-specialty panels and clinical guidelines discussed. Shows HA use of Mainland **classification** but not Mainland **procurement**.

### 3. Health Bureau responds to Consumer Council’s recommendations on price transparency in healthcare (Mar 2025)
**Link:** [Health Bureau responds to Consumer Council](https://www.info.gov.hk/gia/general/202503/06/P2025030600427.htm)  
**Summary:** Government response to Consumer Council study on private healthcare and price transparency. Useful for report context on transparency and consumer trust in healthcare.

### 4. Speech by Secretary for Health at Biopharmaceutical Session of Global Bay Area Economic Forum 2025 (Nov 2025)
**Link:** [Speech by Secretary for Health](https://www.info.gov.hk/gia/general/202511/03/P2025110300542.htm)  
**Summary:** Health chief on GBA and biopharmaceutical development. Complements Policy Address 2025 and GBA clinical trial / drug approval narrative.

### 5. LegCo Research Brief (IN13/2025) — Drug access / procurement
**Link:** [LegCo IN13_2025](https://app7.legco.gov.hk/rpdb/en/uploads/2025/IN/IN13_2025_20250808_en.pdf)  
**Summary:** Research brief on drug access / procurement (Aug 2025). Contains data on HA drug expenditure (e.g. HK$13.1 billion 2023–24, 166% increase over a decade), price gap (e.g. HK$36,000 vs HK$4,000 per month), and advocacy for joint procurement with Mainland. Use for figures and LegCo context.

---

## Media and reports

### 6. RTHK: SMA adult subsidy expansion (Jul 2025)
**Link:** [RTHK – SMA subsidy expansion](https://news.rthk.hk/rthk/en/component/k2/1812936-20250711.htm)  
**Summary:** Reports that Hong Kong health authorities have approved expanding government subsidy eligibility for SMA treatment to **adult patients**. Previously only certain infant/child SMA types could access Nusinersen and Risdiplam subsidies. Lawmaker Michael Tien aims for the new arrangement to be implemented by end 2025. **Important update** on the “age limit 25” issue in LCQ16/LCQ21.

### 7. Hong Kong centre may help fast-track medication approval in mainland China: minister (SCMP, Jun 2024)
**Link:** [SCMP – HK centre fast-track Mainland approval](https://www.scmp.com/news/hong-kong/health-environment/article/3268003/hong-kong-research-centre-may-help-fast-track-medication-approval-mainland-minister)  
**Summary:** Health chief Lo Chung-mau: HK–Shenzhen research centre (GBA International Clinical Trial Institute) will use real-world data from HK to speed up **drug approval in the Mainland**, especially for serious or rare diseases. Complements “1+” and primary-evaluation plans. Shows direction of GBA cooperation (Mainland approval, not HA buying from Mainland).

### 8. Hong Kong & the Greater Bay Area Pharma Report 2024
**Link:** [Pharmaboardroom – HK & GBA Pharma Report 2024](https://pharmaboardroom.com/country-reports/hong-kong-the-greater-bay-area-pharma-report-2024/)  
**Summary:** Commercial/regulatory overview of HK and GBA pharma: “1+” mechanism, timelines, Centre for Medical Products Regulation, GBA clinical trials. Useful for international and industry context.

### 9. China GBA Reimbursement and Regulatory Updates
**Link:** [Cisema – China GBA Reimbursement](https://cisema.com/en/china-gba-reimbursement/)  
**Summary:** GBA integration; Guangdong approved medical products under GBA Connect; reimbursement in several cities. Contrast with “no HA procurement from Mainland” stance in LCQ16.

### 10. Hong Kong Healthcare Drug System (U.S. Trade.gov)
**Link:** [Trade.gov – Hong Kong Healthcare Drug System](https://www.trade.gov/market-intelligence/hong-kong-healthcare-drug-system)  
**Summary:** Overview of HK drug registration, “1+” (e.g. 24 months → 7 months), and regulatory roadmap. Useful for concise description of the regime.

### 11. Price Transparency in Healthcare: Fostering Consumer Trust and Value (Consumer Council)
**Link:** [Consumer Council – Price transparency](https://www.consumer.org.hk/en/advocacy/study-report/private_healthcare_services_study)  
**Summary:** Consumer Council study on private healthcare and price transparency. Supports the “transparency” strand (Option E) and comparison with Mainland price lists in LCQ22.

---

## Already in project (quick reference)

- **LCQ16** (Jun 2024), **LCQ21** (Jun 2024), **“1+” extension** (Oct 2024), **Policy Address 2025**, **LCQ8** (Dec 2024), **LCQ22 HA procurement** (Nov 2024): see `summary2Feb.md`, `moreDocs.md`, `WebSearchReport.md`.
- **SCMP:** “HK patients flocking to Mainland,” “road to treatment is slow,” NHSA Nusinersen price cut, etc.: see `moreDocs.md`.

---

## Suggested use

- Add any of the above links as a **new tab or “Further sources”** section in the Google Doc.
- Cite **RTHK (Jul 2025)** and **LCQ22 (Oct 2025)** in the report when discussing SMA subsidy expansion and drug price transparency.
- Use **LegCo IN13_2025** for aggregate spending and price-gap figures.
- Use **gov.hk** and **Consumer Council** links for official and civil society positions on transparency and reform.

---

*Last updated: 12 Feb 2026. Re-run web search and add new entries as the project continues.*
